PEEL-224 in Solid Tumors
Contact
Description
This study enrolls patients with refractory, progressive, or relapsed solid tumors. The purpose of this study is to find out whether a drug called PEEL-224 ("the study drug") is safe and effective when given as monotherapy (a drug given by itself) and as part of a combination therapy together with other chemotherapy drugs.
Eligibility and criteria
IRB Number:
24-022741
Eligible age range:
Clinical trial phase:
Phase I
Phase II
Official title:
What to expect
Participants in the research will:
- Receive PEEL-224 infusions, either by itself or in combination with other chemotherapy drugs
- Complete frequent clinic visits at CHOP Philadelphia campus
- Have frequent blood tests
- Have periodic imaging performed as part of regular cancer care to evaluate the response to treatment
- Have research genetic tests (if not previously done clinically)
- Submit leftover tissue samples to the study repository
- Complete questionnaires
Related specialties
We need families like you
Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.